


This listing of claims will replace all prior versions, and listings, of claims in the application:


Listing of the Claims:

Claims 1-48 . (Canceled)

49. (Currently amended) A method of treating macular degeneration, which comprises administering to a patient in need thereof a therapeutically effective amount of 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline having the formula:



or a pharmaceutically acceptable salt, solvate or stereoisomer thereof. ~~an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein said immunomodulatory compound is of the formula:~~



in which

Y is oxygen or H₂;

a first of R¹ and R² is halo, alkyl, alkoxy, alkylamino, dialkylamino, cyano, or carbamoyl, the second of R¹ and R², independently of the first, is hydrogen, halo, alkyl, alkoxy, alkylamino, dialkylamino, cyano, or carbamoyl, and

R³ is hydrogen, alkyl, or benzyl.

50-56. (Canceled)

57. (Currently amended) The method of ~~any one of claims 23 to 56~~ claim 49 wherein the method comprises administering a therapeutically effective amount of a second active agent.

58. (Previously presented) The method of claim 57 wherein the second active agent is a steroid, a light sensitizer, an integrin, an antioxidant, an interferon, a xanthine derivative, a growth hormone, a neutrotrophic factor, a regulator of neovascularization, an anti-VEGF antibody, a

prostaglandin, an antibiotic, a phytoestrogen, an anti-inflammatory compound or an antiangiogenesis compound.

59. (Previously presented) The method of claim 57 wherein the second active agent is thalidomide, verteporfin, purlytin, an angiostatic steroid, rhuFab, interferon-2 α or pentoxifylline, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

60. (Previously presented) The method of claim 58 wherein the antiangiogenesis compound is thalidomide.

61. (Currently amended) The method of ~~any one of claims 23 to 56~~ claim 49 wherein the macular degeneration is wet macular degeneration, dry macular degeneration, age-related macular degeneration, age-related maculopathy, choroidal neovascularisation, retinal pigment epithelium detachment, atrophy of retinal pigment epithelium, Best's disease, vitelliform, Stargardt's disease, juvenile macular dystrophy, fundus flavimaculatus, Behr's disease, Sorsby's disease, Doyne's disease, honeycomb dystrophy, or macular damaging condition.

62. (Currently amended) The method of ~~any one of claims 23 to 56~~ claim 49 wherein the ~~immunomodulatory~~ compound is stereomerically pure.

63. (Currently amended) The method of ~~any one of claims 23 to 56~~ claim 49 wherein the ~~immunomodulatory~~ compound is administered before, during or after surgical intervention directed at reducing or avoiding a symptom of macular degeneration in a patient.

64. (Previously presented) The method of claim 63 wherein the surgical intervention is light therapy, laser therapy, retinal pigment epithelium transplantation, or foveal translocation.